Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using… (NCT06629155) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Studying Eye Movement Deficits and Cognitive Impairment in Patients with Multiple Sclerosis Using Infrared Eye Tracking and Cognitive Tests
50 participantsStarted 2025-03-01
Plain-language summary
The goal of this observational study is to study the relationship between cognitive problems and problems in eye movements in Multiple Sclerosis (MS).
The main questions it aims to answer are:
* What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and SDMT scores in patients with MS?
* What is the number of patients with VDI AUC\>1.174 and/or VDI Pv/Am\>1.180 assessed by infrared oculography during prosaccades at 15 degrees left or right?
* What is the correlation between eye movement parameters (VDI AUC and VDI Pv/Am, left and right) and cognitive test scores in patients with MS?
Participants will perform specific cognitive tests and eye movements will be measured through infrared oculography.
The primary hypothesis for the study is: participants who exceed the treshold (VDI AUC\>1.174 and/or VDI Pv/Am\>1.180, left or right) will perform worse on cognitive tests compared to those who don't.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Diagnosed with clinically definite multiple sclerosis according to the 2017 McDonald criteria
* At least 18 years old
* Combined vision with optimal correction \> 0,6 on Snellen Visual Acuity Test.
* Providing informed consent.
Exclusion criteria:
* Major medical or psychiatric pathology that potentially affects cognitive functioning.
* A score higher than 63 on the Fatigue Scale for Motor and Cognitive Functions is categorized as severe fatigue
* Start or switch in immunomodulatory treatment within three months before inclusion.
* Less than 3 months post exacerbation.
* Refusing informed consent.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Correlation between eye movement parameters and SDMT.